FOLD

FOLD is currently tethered to its pending $4.8B all-cash acquisition by BioMarin (BMRN) at $14.50/share, which explains the 'Steady Climb' and bond-like 2.8% annualized volatility. The technical signals are not predicting a growth breakout but rather reflecting the mechanical tightening of the arbitrage spread (currently ~1.1%) as the deal moves toward closing. In the current 'Caution' macro regime, FOLD acts as a defensive cash-substitute, decoupled from the tech sell-off and rising yields.